Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CGEN
STRONG BUYFLAGCompugen Ltd. · Healthcare · Israel · $216M · Avg Vol: $633K/d
Compugen has quality Q67 and value V64, but momentum at M52 misses the all-three-above-60 path, and the insider selling on file rounds to 0.00% and is unusable, so there is no corroboration.
COMPANY DESCRIPTION
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in immunology and oncology, utilizing a proprietary computational discovery platform to identify novel drug targets. Its core strength lies in its predictive biology platform, which allows for the discovery of new immune checkpoints and therapeutic proteins, differentiating it from traditional drug discovery approaches. Compugen is a pioneer in predictive computational discovery, aiming to develop first-in-class immunotherapies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.5M | 33.5M | 27.9M | 72.8M | 113.3% | 72.7M | 10.7M | 7.8M | -67.4% |
| EPS | -0.39 | -0.21 | -0.16 | 0.38 | — | 0.38 | — | — | — |
| Shares | 86.6M | 89.2M | 89.5M | 94.6M | +9.2% | 94.6M | — | — | — |
| Debt | 1.9M | 1.4M | 2.9M | 3.0M | 15.4% | 2.9M | — | — | — |
| Equity | 77.7M | 65.6M | 54.9M | 102.7M | 9.8% | — | — | — | — |
| Op CF | -34.1M | -35.9M | 49.6M | 31.6M | -36.2% | — | — | — | — |
| Inv CF | 37.1M | 35.5M | -46.3M | 30.0M | — | — | — | — | — |
| Fin CF | 0.4M | 3.1M | 0.6M | 10.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CGEN | Compugen Ltd.(you) | $216M | 86 | STRONG BUY |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 34 | SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| ENTX | Entera Bio Ltd. | $101M | 16 | STRONG SELL |
| PYPD | PolyPid Ltd. | $75M | 22 | SELL |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 27 | SELL |
| ENLV | Enlivex Ltd. | $71M | 12 | STRONG SELL |
| 1696.HK | Sisram Medical Ltd | $134M | 90 | STRONG BUY |
| KMDA | Kamada Ltd. | $407M | 85 | STRONG BUY |
| INMD | InMode Ltd. | $872M | 93 | STRONG BUY |
Peer medians: ROE -2.9% · P/E 20.7x · Gross margin 19.6%